Insmed (INSM)
Insmed Capital Expenditures: 0.066M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
INSM Capital Expenditures Rankings
| Overall | 74th percentile | 1153 of 4457 |
| Sector | 64th percentile | 180 of 507 in Healthcare |
| Industry | 53rd percentile | 74 of 158 in Biotechnology |
INSM Capital Expenditures Range, Past 5 Years
| Minimum | 0.00 | Jun 2007 |
| Maximum | 0.487M | Sep 2011 |
| Average | 0.0522M |
About Capex
Capital expenditures are a line item from a company's statement of cash flows (click "Learn More" below for details).
Capex (short for capital expenditures) are incurred when a business spends money to purchase fixed assets or to add value to an existing fixed asset. In accounting, a capital expenditures are added to an asset account, thus increasing the value of the asset.
Examples of capital expenditures include the purchase of a new manufacturing plant, investment in server farms for tech companies, or other purchases of assets expected to help the company earn profits in the future.
Unlike other investments like research and development and marketing spending, capital expenditures are not immediately expensed. Rather, property, plant and equipment acquired using capital expenditures are usually expensed over time through the use of depreciation.
Learn More
You may also be interested in these INSM related companies
INSM News
$INSM 200 Day SMA Cross - Price crossed above 200 day SMA (4.0927). Confirmed by volume.
about 22 days ago by TradeIdeasQuant
about 22 days ago by TradeIdeasQuant
Listen to $INSM Q1 2012 earnings call - live at 08:30 AM, ondemand after - http://stks.co/3iQw
about 22 days ago by earningscast
about 22 days ago by earningscast
$insm took a few short here..might crack into the close http://stks.co/3hmM
about 23 days ago by kunal00
about 23 days ago by kunal00
started into small short on $INSM 4.89 will add in the low 5's target 4
about 23 days ago by LincolnList
about 23 days ago by LincolnList
Insmed $INSM Says Clinical Hold on ARIKACE in CF Patients Lifted
about 23 days ago by Street_Insider
about 23 days ago by Street_Insider
$INSM filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3HoE
about 50 days ago by MarketBrief
about 50 days ago by MarketBrief
Listen to $INSM Q4 2011 earnings call - live at 08:30 AM, ondemand after - http://stks.co/2oMs
about 78 days ago by earningscast
about 78 days ago by earningscast
Insmed (INSM) Commences ARIKACE Phase 2 in NTM Lung Disease Patients, Phase 3 in CF Patients w/ Pa
Feb 10, 8:05AM Street Insider
Feb 10, 8:05AM Street Insider
steppin out to meet tax man.....have order waitin on $INSM if it goes low enough
about 127 days ago by highgrowthfinancial
about 127 days ago by highgrowthfinancial
$INSM could of had 3k @$3.74, stubbornly left bid @$3.73...didn't fill 1 share.WTF! finished strong. will take another look tues
about 128 days ago by highgrowthfinancial
about 128 days ago by highgrowthfinancial
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| INSM | 2.95 | -0.02 | -0.67% | 73.83M |
| INSD | 39.03 | +0.00 | +0.00% | |
| INS | 1.64 | +0.00 | +0.00% | 14.69M |
| INPH | 4.79 | -0.17 | -3.43% | 34.27M |
| INOD | 5.51 | -0.05 | -0.90% | 137.28M |
| INOC | 1.32 | +0.00 | +0.00% | 17.17M |
| INO | 0.44 | -0.01 | -2.22% | 59.39M |
| ININ | 25.90 | -0.26 | -0.99% | 500.44M |
| ING | 5.795 | -0.26 | -4.21% | 22.88B |
| IMN | 5.63 | -0.05 | -0.88% | 217.71M |
